Jeffrey R. Marks

Other J Clin Oncol · February 10, 2007 PURPOSE: The purpose of this study was to develop an integrated genomic-based approach to personalized treatment of patients with advanced-stage ovarian cancer. We have used gene expression profiles to identify patients likely to be resistant to primary pl ... Full text Link to item Cite

Genomic signatures to guide the use of chemotherapeutics.

Other Nat Med · November 2006 Using in vitro drug sensitivity data coupled with Affymetrix microarray data, we developed gene expression signatures that predict sensitivity to individual chemotherapeutic drugs. Each signature was validated with response data from an independent set of ... Full text Link to item Cite

Prediction of optimal versus suboptimal cytoreduction of advanced-stage serious ovarian cancer with the use of microarrays

Other Women S Oncology Review · September 1, 2004 Full text Cite

Relationship between alterations in the p53 gene and chemosensitivity of ovarian cancers

Other CME Journal of Gynecologic Oncology · December 1, 1999 It is thought that the cytotoxic effect of chemotherapy drugs is largely due to their ability to initiate programmed cell death (apoptosis). Although the molecular pathways involved in regulation of apoptosis have not been completely elucidated, it has bee ... Cite